Skip to content Skip to footer
Subscribe Now
Viewpoints_Phil Lambert
VIEWPOINTS

Enhancing DMD Care: Phil Lambert from Satellos in a Riveting Conversation with PharmaShots

Shots:  Conventional therapeutic models for Duchenne Muscular Dystrophy (DMD) primarily focus on the role of dystrophin in maintaining muscle cell integrity. However, Satellos’ SAT-3247 takes a novel approach, targeting the lack of dystrophin in muscle stem cells to restore muscle fiber regeneration and repair  Today at PharmaShots, we are joined by Phil Lambert, Chief Scientific…
November 20, 2024

Read more

Viewpoints_Samuel Gidding_Allison Jamison
VIEWPOINTS

Bringing Awareness to the Public: Samuel S. Gidding & Allison Jamison in an Enlightening Conversation with PharmaShots

Shots:  Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic condition that affects approximately 1 in 250,000 Americans. It is characterized by the presence of two genetic mutations that lead to extremely high levels of LDL cholesterol.  In this interview, Sam Gidding and Allison Jamison from the Family Heart Foundation/ emphasize the critical need for enhanced…
November 18, 2024

Read more

Announcements

PharmaShots Secures Prestigious Bharat Business Award 2024 

PharmaShots is pleased to announce that we have been honored with the Best Healthcare and Pharma Digital Media Management award under the Bharat Business Awards 2024 category, organized by WEECE Entertainment and Events Pvt. Ltd.  This recognition is a testament to the dedication, resilience, and hard work of our team. We are deeply grateful to our clients for their continued…
November 14, 2024

Read more

THOUGHTSPOT

Bridging the Biopharma Gap with Consulting Firms

Shots:  In the extremely competitive biopharma industry, it’s never too soon to learn about the players who help biopharma companies understand the evolving landscape of the biopharma industry  Consulting firms are instrumental in guiding biopharma companies in decision-making, understanding the regulatory challenges, and market dynamics  This article from PharmaShots unfolds the benefits of onboarding a…
November 13, 2024

Read more

Viewpoints_Jason Lerner
VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots:  Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies  Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…
November 6, 2024

Read more

Viewpoints_Fred Aslan
VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots:  Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases  Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…
November 4, 2024

Read more

Viewpoints_Adityo Prakash
VIEWPOINTS

AI in Drug Discovery: Adityo Prakash from Verseon in an Illuminating Dialogue Exchange with PharmaShots

Shots:  AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs  Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models  Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…
October 30, 2024

Read more

New Drug Designations - September 2024
INSIGHTS+

New Drug Designations – September 2024

Shots:   PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA, Health Canada and EMA.  The September 2024 report covers regulatory designations for 42 drugs and 1 device, including 16 small molecules, 6 biologics, 12 cell and gene therapies, and 1 device, among others.  Significant trends this month…
October 29, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots:  Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032.  The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD.  In collaboration with…
October 28, 2024

Read more

Viewpoints_Baldo Scassellati Sforzolini
VIEWPOINTS

Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study.  Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024

Read more

Load more